C07K 16/00
Immunoglobulins [ig]
Official title: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
C07K16/00 (Immunoglobulins [ig]) appears on 46,944 US grants and 80,612 published applications in this corpus.
Search patents in C07K- Granted patents
- 46,944
- Published applications
- 80,612
- Assignees
- 13,973
- Inventors
- 94,136
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 20 | 0 |
| 1977 | 14 | 0 |
| 1978 | 26 | 0 |
| 1979 | 20 | 0 |
| 1980 | 24 | 0 |
| 1981 | 30 | 0 |
| 1982 | 45 | 0 |
| 1983 | 23 | 0 |
| 1984 | 63 | 0 |
| 1985 | 50 | 0 |
| 1986 | 64 | 0 |
| 1987 | 136 | 0 |
| 1988 | 131 | 0 |
| 1989 | 192 | 0 |
| 1990 | 159 | 0 |
| 1991 | 184 | 0 |
| 1992 | 254 | 0 |
| 1993 | 366 | 0 |
| 1994 | 283 | 0 |
| 1995 | 294 | 0 |
| 1996 | 452 | 0 |
| 1997 | 784 | 0 |
| 1998 | 1026 | 0 |
| 1999 | 854 | 0 |
| 2000 | 719 | 0 |
| 2001 | 738 | 205 |
| 2002 | 675 | 1218 |
| 2003 | 592 | 2947 |
| 2004 | 562 | 1606 |
| 2005 | 485 | 1809 |
| 2006 | 771 | 1802 |
| 2007 | 893 | 1713 |
| 2008 | 899 | 1703 |
| 2009 | 933 | 2274 |
| 2010 | 1161 | 2363 |
| 2011 | 1223 | 2507 |
| 2012 | 1302 | 2411 |
| 2013 | 1518 | 2640 |
| 2014 | 1691 | 3190 |
| 2015 | 1800 | 3143 |
| 2016 | 1951 | 3601 |
| 2017 | 2166 | 3656 |
| 2018 | 2119 | 3775 |
| 2019 | 2358 | 4380 |
| 2020 | 2590 | 4655 |
| 2021 | 2571 | 5062 |
| 2022 | 2476 | 5047 |
| 2023 | 2250 | 5029 |
| 2024 | 2549 | 5475 |
| 2025 | 2618 | 4709 |
| 2026 | 1840 | 3692 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 16/18Against material from animals or humans36,051
- C07K 16/40Against enzymes3,886
- C07K 16/08Against material from viruses3,399
- C07K 16/12Against material from bacteria2,455
- C07K 16/46Hybrid immunoglobulins2,367
- C07K 16/44Against material not provided for elsewhere1,686
- C07K 16/42Against immunoglobulins1,088
- C07K 16/06From serum1,006
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Treatment of clonal hematopoietic disorders using kinase inhibitors8 Oct 2026US 2026/0306462 A1
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Single polypeptide chain binding molecules2,454US 4,946,778 AGenex Corporation · 1990
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997